Since the clinical benefits of immune checkpoint inhibitors (ICIs) in improving patient outcomes in advanced cervical cancer were established, many countries, especially in high-income areas of the world, have outlined guidelines for the effective use of ICI therapy in cervical cancer patients with PD-L1 expression. This evidence concerns the gene CD274 and cervical cancer.